AMT Accesses Technology for Treatment of Duchenne Muscular...(management's plans andexpectations for f...)

Date:5/21/2008

management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement and success of AMT's clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMEA, Health Canada), market acceptance of AMT's products, effectiveness of AMT's marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals and consents. AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer to the prospectus of AMT's initial public offering on June 20, 2007, and AMT's public announcements made from time to time.

'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V Copyright©2008 PR Newswire. All rights reserved

2 GOOD

Page: 1 2 3
Related biology technology :

1. Pharmasset Accesses up to $30 Million of Working Capital
2. DolmatConnell & Partners 2008 Studies of CEO and CFO Compensation in the 100 Largest High Technology and Life Science Companies Show Dramatically Improving Link Between Pay and Performance
3. Naviscan PET Systems and Rockville PET Imaging Partner to Bring a New Breast Imaging Technology to New York
4. eResearchTechnology to Present at the FBR 12th Annual Spring Investor Conference on May 28th 2008
5. NASA Nanotechnology-Based Biosensor Helps Detect Biohazards
6. eResearchTechnology Announces Resignation of its CFO
7. American Oriental Bioengineering Forms Science and Technology Advisory Committee
8. Record Venture Capital and Heated Deal Environment Propel Global Biotechnology Industry Forward in 2007
9. Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery
10. Kiwa Bio-Tech in Collaboration Discussions with Beijing Hai Xin Science and Technology Co., Ltd.
11. Chromatide and Novasep Have Extended Their Partnership to Develop Large Scale Solid Phase Peptide and Oligonucleotide Synthesis Technology.